PUBLISHER: TechNavio | PRODUCT CODE: 1559394
PUBLISHER: TechNavio | PRODUCT CODE: 1559394
Doxorubicin Market 2024-2028
The doxorubicin market is forecasted to grow by USD 497.4 mn during 2023-2028, accelerating at a CAGR of 6.09% during the forecast period. The report on the doxorubicin market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of cancer cases, increasing product launches of doxorubicin, and advancements in diagnostic methods.
Market Scope | |
---|---|
Base Year | 2024 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 5.65% |
CAGR | 6.09% |
Incremental Value | $497.4 mn |
Technavio's doxorubicin market is segmented as below:
By Formulation
By Distribution Channel
By Geographical Landscape
This study identifies the introduction of precision cancer medicine as one of the prime reasons driving the doxorubicin market growth during the next few years. Also, rise in research and development of innovative biologics and increasing inorganic growth strategies by vendors will lead to sizable demand in the market.
The report on the doxorubicin market covers the following areas:
The vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading doxorubicin market vendors that include Aurobindo Pharma Ltd., Baxter International Inc., Cipla Inc., DR Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Johnson and Johnson Services Inc., Meiji Holdings Co. Ltd., Merck KGaA, Mitsui and Co. Ltd., Novartis AG, Pfizer Inc., Pharmagen CZ s.r.o, S. G. Biopharm Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Synbias Pharma AG, Teva Pharmaceutical Industries Ltd., TTY Biopharm Co. Ltd., and Zydus Lifesciences Ltd.. Also, the doxorubicin market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Exhibits: